Q-omics provides the consensus-scored PPP1CC profile across patient tissues and cancer cell-line models. PPP1CC expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, PPP1CC is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, PPP1CC RNA expression shows 19,658 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, KIRC, and ACC as cancer lineages where PPP1CC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPP1CC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPP1CC survival associations across molecular data types. PPP1CC RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPP1CC RNA expression–survival associations across cancer types. High PPP1CC expression shows unfavorable associations in LIHC, ACC, KICH and KIRP, but favorable associations in UCS and KIRC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for PPP1CC RNA expression.
This table summarizes PPP1CC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PPP1CC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPP1CC shows lower tumor expression in THCA and higher tumor expression in KIRC, KIRP, LIHC, LUSC and HNSC. The KIRC box plot shows higher PPP1CC RNA expression in tumor versus normal tissue (log2 FC = +0.761, t-test p < 0.001).
This table shows molecular features associated with PPP1CC in patient tissues and cancer cell lines. In patient samples, PPP1CC shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PPP1CC RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and UPPER_AERODIGESTIVE_TRACT.
